NCT05057468View on ClinicalTrials.gov

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

November 1, 2026

Study Completion Date

November 30, 2026

Conditions
Primary Autoimmune Hemolytic Anemia
Interventions
DRUG

Cyclosporine

2.5-5 mg orally for 3 months

DRUG

Rituximab

375 mg/ m2 weekly dose for a maximum of 4 weeks

Trial Locations (2)

17111

ACTIVE_NOT_RECRUITING

Assiut university hospital, Asyut

Unknown

RECRUITING

Assiut university hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER